Literature DB >> 6361125

In vitro and in vivo studies on protective and inhibitory antibodies against Plasmodium falciparum in the Saimiri monkey.

T Fandeur, P Dubois, J Gysin, J P Dedet, L P da Silva.   

Abstract

Immunoglobulins (Ig) were purified from serum or ascitic fluids of Saimiri monkeys infected with Plasmodium falciparum and with differing levels of functional immunity. Their protective activity was assessed in studies of passive transfer of immunity in vivo, and their neutralizing activity was measured in studies of parasite inhibition in vitro in cultures of human or Saimiri RBC. Although protective and inhibitory antibodies were detected in different Ig preparations, the levels of these activities were not directly correlated. Some Ig preparations, showing high protective activity, provide little or no inhibition of the parasite in vitro. Conversely, inhibitory activity was present in Ig preparations unable to confer protection in vivo. These results indicate that protective antibodies are active through a more complex immune mechanism than simple neutralization probably involving cellular immunity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6361125

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Long-term protection of squirrel monkeys (Saimiri sciureus) against Plasmodium falciparum challenge inoculations after various time intervals.

Authors:  C Roussilhon; T Fandeur; J P Dedet
Journal:  Parasitol Res       Date:  1988       Impact factor: 2.289

2.  Antibody and clinical responses in volunteers to immunization with malaria peptide-diptheria toxoid conjugates.

Authors:  R Ramasamy; D A Wijesundere; K Nagendran; M S Ramasamy
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

3.  Passive immunization of Aotus monkeys with human antibodies to the Plasmodium falciparum antigen Pf155/RESA.

Authors:  K Berzins; H Perlmann; B Wåhlin; H P Ekre; B Högh; E Petersen; B Wellde; M Schoenbechler; J Williams; J Chulay
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

4.  Anti-idiotypic antibodies counteract the invasion inhibition capacity of antibodies to major epitopes of the Plasmodium falciparum antigen Pf155/RESA.

Authors:  B Wåhlin; K Berzins; H Perlmann; R F Anders; P Perlmann
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

5.  High immunoglobulin G2 (IgG2) and low IgG4 levels are associated with human resistance to Plasmodium falciparum malaria.

Authors:  C Aucan; Y Traoré; F Tall; B Nacro; T Traoré-Leroux; F Fumoux; P Rihet
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

6.  Induction of protective immunity to Plasmodium falciparum in Saimiri sciureus monkeys with partially purified exoantigens.

Authors:  M A James; I Kakoma; M Ristic; M Cagnard
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

7.  Immunization of cattle with a 36-kilodalton surface protein induces protection against homologous and heterologous Anaplasma marginale challenge.

Authors:  G H Palmer; S M Oberle; A F Barbet; W L Goff; W C Davis; T C McGuire
Journal:  Infect Immun       Date:  1988-06       Impact factor: 3.441

8.  Induction of opsonizing antibodies after injection of recombinant Plasmodium falciparum vaccine candidate antigens in preimmune Saimiri sciureus monkeys.

Authors:  R Perraut; O Mercereau-Puijalon; D Mattei; E Bourreau; O Garraud; B Bonnemains; L Pereia de Silva; J C Michel
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

9.  Recent progress in the development of malaria vaccines: memorandum from a WHO meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1984       Impact factor: 9.408

10.  Human antibodies to a Mr 155,000 Plasmodium falciparum antigen efficiently inhibit merozoite invasion.

Authors:  B Wåhlin; M Wahlgren; H Perlmann; K Berzins; A Björkman; M E Patarroyo; P Perlmann
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.